- JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more
- JPM 2022: Pfizer locks in 2 partners to solidify status as mRNA powerhouse
- BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
- JPM 2022: Bayer taps CRISPR science from Doudna's lab in $1B biobucks Mammoth gene therapy deal
- Maze Therapeutics navigates $190M financing round as it plots course to the clinic
- Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, death
- JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal
- JPM 2022: Acadia to Stoke up pipeline with $60M central nervous system research pact
- JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more
- Fierce Healthcare's Fierce 15 of 2022
- MeMed secures $93M to deliver tests for identifying viral, bacterial infections
- JPM, Day 1: Teladoc 2021 revenue to hit $2B, R1 RCM picks up Cloudmed in deal valued at $4.1B and more
Featured Story | By Ben Adams,Annalee Armstrong,Conor Hale,Kyle LaHucik Join us for a rolling look at the top life sciences news coming out of this year's virtual J.P. Morgan healthcare conference. read more |
| |
|---|
|
| 
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
Top Stories By Annalee Armstrong Pfizer is determined to become an mRNA powerhouse, and it’s signing on two partners in that quest, including one that supplied tech that helped create the COVID-19 vaccine. read more By Nick Paul Taylor Sixteen months after a stinging FDA rejection, BioMarin Pharmaceutical looks to have the data it needs to win approval for its hemophilia A gene therapy in the U.S. The study found bleeding episodes remained very rare two years after the administration of valoctocogene roxaparvovec (ValRox). read more By Angus Liu Bayer is adding more building blocks to its cell and gene therapy ambition by tapping Mammoth Biosciences' CRISPR gene editing toolbox in a strategic collaboration with $40 million upfront and potentially worth over $1 billion. read more By Fraiser Kansteiner Fierce 15 winner Maze Therapeutics just added $190 million to its fundraising pile in time to help its lead candidate, MZE001 for Pompe disease, make a clinical debut. Since its launch in 2019, the company ginned up approximately $400 million in investor cash. read more By Nick Paul Taylor Novartis is coming for the COVID-19 antiviral market. After failing in hospitalized patients, Molecular Partners linked ensovibep to a 78% risk reduction in an earlier-stage population, prompting Novartis to pay 150 million Swiss francs ($163 million) for an asset that could soon add to the anti-omicron arsenal. read more By Annalee Armstrong Moderna is doling out a little bit of its COVID-19 vaccine cash in a $45 million oncology research deal with Carisma Therapeutics to develop up to a dozen targets. read more By Annalee Armstrong Acadia is looking to Stoke Therapeutics to breathe some air into its pipeline, with a $60 million upfront research pact to develop drugs for rare genetic diseases of the central nervous system. The upfront fee is accompanied by up to $907 million in milestones and also royalties down the line for Stoke. read more By Eric Sagonowsky,Fraiser Kansteiner,Kevin Dunleavy,Angus Liu Boot up those computers and get your J.P. Morgan healthcare conference meeting links ready, because it's set to be a week full of biopharma action. read more By Paige Minemyer Meet the winners of Fierce Healthcare's Fierce 15 of 2022. read more By Conor Hale While most infectious disease tests search a sample for the presence of a particular pathogen, MeMed’s diagnostic collects evidence from the immune system itself and helps identify the culprit by gauging the body’s response to an invader. read more By Heather Landi,Paige Minemyer,Dave Muoio,Robert King,Rebecca Torrence,Anastassia Gliadkovskaya Advocate Aurora gave an update on the non-profit hospital chain's efforts to pivot to a consumer-related healthcare company, including new acquisitions in technology providers. read more Resources Sponsored by: WIRB-Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Immuno-Oncology 360° Summit March 16-18, 2022 | New York Marriott Brooklyn Bridge Fierce JPM Week 2022 January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA | Presented by Fierce Pharma
February 16-17, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Summit May 16-17, 2022 | Boston, MA Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 2022 | Location TBD | 
